Last Updated: August 25, 2026

Drug Price Trends for QC NIGHTTIME COLD-FLU SOFTGEL


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for QC NIGHTTIME COLD-FLU SOFTGEL

Average Pharmacy Cost for QC NIGHTTIME COLD-FLU SOFTGEL

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
QC NIGHTTIME COLD-FLU SOFTGEL 83324-0148-24 0.11958 EACH 2026-07-22
QC NIGHTTIME COLD-FLU SOFTGEL 83324-0148-24 0.11816 EACH 2026-06-17
QC NIGHTTIME COLD-FLU SOFTGEL 83324-0148-24 0.12029 EACH 2026-05-20
QC NIGHTTIME COLD-FLU SOFTGEL 83324-0148-24 0.11960 EACH 2026-04-22
QC NIGHTTIME COLD-FLU SOFTGEL 83324-0148-24 0.12018 EACH 2026-03-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for QC NIGHTTIME COLD-FLU SOFTGEL

Last updated: February 15, 2026

Market Overview

QC NIGHTTIME COLD-FLU SOFTGEL is a consumer healthcare product designed to alleviate symptoms associated with cold and flu, primarily targeting nighttime relief. Its formulation likely includes a combination of analgesics, antihistamines, decongestants, and sleep aids. The product's positioning in the over-the-counter (OTC) cold and flu segment puts it amid a competitive landscape with both branded and private-label alternatives.

Market Size and Segmentation

The global OTC cold and flu medicine market was valued at approximately USD 11.8 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 3.5% from 2023 to 2030 [1]. North America accounts for 40% of the total market, driven by high consumer health awareness and established regulatory frameworks.

Within this, the segment focusing on nighttime relief formulations, especially in softgel or capsule forms, is expanding. Softgels are preferred for their quicker absorption and ease of swallowing, especially among older consumers.

Competitive Landscape

Key brands include Tylenol Nighttime, NyQuil, Advil Nighttime, and Walgreens or CVS store brands. These products typically retail at USD 8-12 per package of 12-20 softgels, depending on formulation complexity and branding.

Private-label options are increasingly capturing market share by offering similar efficacy at lower prices, often USD 6-10 per package.

Regulatory Considerations

The OTC status of cold/flu formulations involves compliance with regulations from agencies like the FDA (U.S.) or EMA (Europe). In the U.S., the formulation must adhere to monographs or undergo new drug application (NDA) approval if it contains novel combinations or ingredients.

Product labeling and safety monitoring influence pricing strategies, with higher regulatory costs potentially translating into higher retail prices.

Pricing Strategies and Projections

Current retail pricing for similar products ranges from USD 8 to USD 12 per package in the U.S., with margins typically around 30-50%. The price of QC NIGHTTIME COLD-FLU SOFTGEL will likely be influenced by:

  • Formulation complexity: Combining multiple active ingredients increases costs.
  • Brand positioning: Established brands command higher prices.
  • Distribution channels: Pharmacy and online channels can command premiums.
  • Market demand: Seasonal peaks in cold and flu seasons impact pricing flexibility.

Based on historical data and competitive positioning, the initial retail price is projected at USD 9-10 per package for a 12-20 softgel pack.

Future Price Trends

Over the next five years, the following factors will influence price trends:

  1. Market growth: A steady CAGR of 3.5%, with increased demand during colder months.
  2. Ingredient costs: Fluctuations in active ingredient prices could lead to price adjustments.
  3. Regulatory changes: Stricter labeling or safety requirements might raise costs.
  4. Competitive pressure: Private-label expansion could compress margins, stabilizing or reducing prices.

Expect prices to remain within USD 8-12 range, with minor fluctuations based on seasonality and market dynamics.

Potential Impact of New Entrants and Innovation

Introduction of novel formulations or sustained release softgels may command premium pricing (USD 12-15), especially if clinical trials demonstrate enhanced efficacy or safety. Conversely, commoditized formulations are likely to push prices downward due to generic and private-label competition.

Summary

Factor Effect on Price
Formulation complexity Slight increase
Brand strength Higher pricing
Distribution channel Escalates price via pharmacy/online
Competitive landscape Pushes towards lower end
Ingredient costs Variable, may raise costs

Key Takeaways

  • The OTC cold/flu softgel market is mature, with established brands dominant.
  • Expected retail price for QC NIGHTTIME COLD-FLU SOFTGEL: USD 9-10 per package.
  • Price stability expected, with potential slight reductions due to private-label competition.
  • Regulatory and ingredient cost fluctuations may influence future pricing.
  • Innovation and product differentiation could command premiums.

FAQs

What is the primary competitive advantage of QC NIGHTTIME COLD-FLU SOFTGEL?
Its formulation, targeting nighttime symptom relief, combined with softgel delivery, appeals to consumers seeking quick absorption and convenience.

How do ingredient costs influence retail prices?
Rising costs for active ingredients, especially if sourced globally, may force manufacturers to increase retail prices or absorb costs.

What role do regulatory policies play in pricing?
Stricter regulations can elevate compliance expenses, potentially raising retail prices, especially if new safety standards are introduced.

Will private-label products impact pricing?
Yes. Private-labels tend to be priced 10-20% lower than branded counterparts, pressuring branded products to maintain competitive prices.

What is the forecast for product innovation in this segment?
Innovations like sustained-release softgels or natural ingredient blends could justify higher prices but depend on clinical efficacy and regulatory acceptance.


Sources

[1] Grand View Research, "Over-the-Counter (OTC) Cold & Flu Medicine Market Size, Share & Trends Analysis," 2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.